Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma



Status:Completed
Conditions:Lymphoma, Lymphoma
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:July 2006
End Date:January 2009

Use our guide to learn which trials are right for you!

Open-Label, Multicenter, Phase 1/2 Dose-Escalation Study of AME-133v (LY 2469298), Administered Intravenously in Four Weekly Doses, in Subjects With CD20+ Follicular Relapsed or Refractory Non-Hodgkin's Lymphoma

This study is designed to provide evidence of the safety and a preliminary understanding of
the efficacy of AME 133v.

The protein engineering of AME-133v is hypothesized to result in an anti-CD20 therapy with
greater potency and efficacy in all patients, but particularly in genetically defined
subpopulations that respond poorly to rituximab because they express a low affinity version
of the Fc receptor on their immune effector cells. A monoclonal antibody that has increased
binding for this receptor should be more effective in stimulating effector cell killing and
thus improve response to the antibody.

Inclusion Criteria:

To be included in the study protocol, subjects have to meet all of the following criteria.

- Have morphologically confirmed diagnosis of CD-20+ follicular B-cell non-Hodgkin's
lymphoma;

- Have the low affinity form of FcγRIIIa (F/F or F/V at position 158) as determined by
FcR genotyping;

- Have measurable disease. Measurable masses (such as enlarged lymph nodes) must have a
clearly defined bi-dimensional diameter of at least 1.5 x 1.5 cm on physical
examination or ≤ 1.5 cm in one of the dimensions by CT, MRI, or plain radiograph;

- Have received prior treatment with chemotherapy given without rituximab; OR, Have not
relapsed or progressed within 120 days (inclusive) of the last infusion of rituximab;

- Be 18 years of age or greater;

- Have a negative pregnancy test, if relevant. Women of childbearing potential (not
postmenopausal for at least one year and not surgically incapable of bearing
children) must agree not to become pregnant for the duration of the study. To do
this, they must agree to use a medically acceptable contraceptive regimen;

- Have a performance status of 0 to 2 on the ECOG performance scale;

- Have adequate hematopoietic, renal, and hepatic function defined as:

1. Absolute neutrophil count greater than 1,500/mm³;

2. Platelet count greater than 75,000/mm³;

3. Hemoglobin at least 8 g/dL;

4. Serum creatinine ≤ 1.5x upper limit of normal;

5. Total bilirubin ≤ 1.5x upper limit of normal;

6. ALT ≤ 1.5 x upper limit of normal;

7. Alkaline phosphatase ≤ 1.5x upper limit of normal.

- No evidence of hepatitis B or C infection (no detectable HBV DNA or HCV RNA);

- Have discontinued all previous therapies for cancer, including chemotherapy,
radiotherapy, or other investigational therapy for at least 30 days prior to study
enrollment;

- Have discontinued all high-dose corticosteroid therapy at least 30 days prior to
study enrollment (≤ 10 mg/day of Prednisone or equivalent is allowable);

- Have life expectancy of more than 3 months;

- Be able to give written informed consent.

Exclusion Criteria:

Subjects with any of the following exclusions are not allowed to participate in the study.

- Allergy to monoclonal antibodies or any of the study drug components;

- Concurrent malignancy that could complicate interpretation of response evaluation,
including any histologic evidence of diffuse B-cell lymphoma. Non-melanoma skin
cancer and carcinoma in situ of the cervix are not exclusions;

- Significant cardiac disease (e.g. NYHA CHF of class III or IV, history of MI within
one year prior to study Day 1, unstable angina, uncontrolled hypertension, clinically
significant cardiac arrhythmia (CTCAE Grade 2 or higher), or clinically significant
baseline ECG or MUGA abnormality.

- Positive test for serum cardiac troponins (cTnI or cTnT assay; special processing
required, and the same assay must be used throughout the study; see Study Reference
Manual)

- Active infection requiring oral or i.v. antibiotics;

- Administration of blood transfusions or red blood cell growth factors within 10 days
preceding enrollment into the protocol;

- Administration of white cell growth factors within 28 days preceding enrollment into
the protocol;

- Concomitant nonmalignant disease(s) which could interfere with implementation of the
protocol, make the study results difficult to interpret, or which represent
additional safety risks;

- History of HIV-associated non-Hodgkin's lymphoma.
We found this trial at
11
sites
3322 West End Avenue
Nashville, Tennessee 37203
(615)329-SCRI (7274)
Sarah Cannon Research Institute Sarah Cannon Research Institute (SCRI) is a global strategic research organization...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
101 Jessup Hall
Iowa City, Iowa 52242
(319) 335-3500
University of Iowa With just over 30,000 students, the University of Iowa is one of...
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
Birmingham, Alabama 35233
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
1215 Lee St
Charlottesville, Virginia 22903
(434) 924-0211
University of Virginia Health System UVA Health System includes a 604-bed hospital, level I trauma...
?
mi
from
Charlottesville, VA
Click here to add this to my saved trials
1653 W. Congress Parkway
Chicago, Illinois 60612
(312) 942-5000
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
2049 E 100th St
Cleveland, Ohio 44106
(216) 444-2200
Cleveland Clinic Foundation The Cleveland Clinic (formally known as The Cleveland Clinic Foundation) is a...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Las Vegas, Nevada 89135
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Los Angeles, California 90095
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19111
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
200 Lothrop St
Pittsburgh, Pennsylvania 15213
University of Pittsburgh Medical Center UPMC is one of the leading nonprofit health systems in...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
300 Pasteur Dr
Stanford, California 94305
(650) 723-4000
Stanford Univ Med Ctr The Medical Center is uniquely advantaged by its location on the...
?
mi
from
Stanford, CA
Click here to add this to my saved trials